Aclaris Therapeutics Inc (FRA:8AT)
€ 0.9182 -0.0174 (-1.86%) Market Cap: 66.10 Mil Enterprise Value: -42.89 Mil PE Ratio: 0 PB Ratio: 0.51 GF Score: 50/100

Aclaris Therapeutics Presents 6-Month Results From Androgenetic Alopecia Study Transcript

Jun 17, 2019 / 12:00PM GMT
Release Date Price: €4.09 (-3.31%)
Operator

Good day, ladies and gentlemen, and welcome to the Aclaris presents 6-months results from androgenetic alopecia study. (Operator Instructions) I would now like to introduce your host for today's conference, Ms. Kamil Ali-Jackson.

Kamil Ali;Jackson
Aclaris Therapeutics, Inc. - Co-Founder, Chief Legal Officer, Chief Compliance Officer & Secretary

Thank you. I'm Kamil Ali-Jackson, Chief Legal Officer for Aclaris. Please note that earlier today Aclaris issued its press release announcing 6-months results from our androgenetic alopecia clinical trial, known as AGA-201 for ATI-502, an investigational topical drug candidate, which we're evaluating as a potential treatment for AGA. For those of you who've not yet seen it, you will find the release posted in the Investors section of our website at www.aclaristx.com.

Joining me today for the call are Dr. Neal Walker, President and Chief Executive Officer; Dr. Stuart Shanler, our Chief Scientific Officer; and Dr. David Gordon,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot